Regulon: R-1408
Regulons are regulatory units consisting of a coherently expressed set of genes and the associated regulator(s) whose binding site(s) they share.
Regulon Summary
Regulon summary table displays all associated information related to the specific regulon including the number of genes in the regulon, Hazard ratio, its Regulator, the Transcriptional Program that includes the regulon, Drugs that are associated with members of the regulon, together with mechanism of action and class, and enriched hallmarks of cancer if any.
| Genes | Cox Hazard Ratio | Regulators | Causal Flows | Transcriptional Programs | Hallmarks |
|---|---|---|---|---|---|
| 20 | 2.82218 | 1 | 7 | Pr-85 |           |
Regulon Genes
List of genes that are included in the regulon. These genes have similar expression profiles in subset of patients and they share common binding motif for the Regulator of the regulon. Clicking on the gene name will take you to the gene specific page with more details. Please wait while information is collated from several resources after you click.
Regulon Drugs
| Name | Approved Symbol | Type | Action Type | Mechanism of Action | Max Trial Phase | Max GBM Phase |
|---|---|---|---|---|---|---|
| CISATRACURIUM | CHRNA1 | Small molecule | ANTAGONIST | Muscle-type nicotinic acetylcholine receptor antagonist | 4 | 0 |
| GSK-1995057 | TNFRSF1A | Antibody | INHIBITOR | Tumor necrosis factor receptor R1 inhibitor | 1 | 0 |
| CISATRACURIUM BESYLATE | CHRNA1 | Small molecule | ANTAGONIST | Muscle-type nicotinic acetylcholine receptor antagonist | 4 | 0 |
| SUXAMETHONIUM | CHRNA1 | Small molecule | AGONIST | Muscle-type nicotinic acetylcholine receptor agonist | 4 | 0 |
| BRINZOLAMIDE | CA2 | Small molecule | INHIBITOR | Carbonic anhydrase II inhibitor | 4 | 0 |
| DORZOLAMIDE HYDROCHLORIDE | CA2 | Small molecule | INHIBITOR | Carbonic anhydrase II inhibitor | 4 | 0 |
| DICHLORPHENAMIDE | CA4 | Small molecule | INHIBITOR | Carbonic anhydrase IV inhibitor | 4 | 0 |
| MIVACURIUM | CHRNA1 | Small molecule | ANTAGONIST | Muscle-type nicotinic acetylcholine receptor antagonist | 4 | 0 |
| SULTHIAME | CA2 | Small molecule | INHIBITOR | Carbonic anhydrase inhibitor | 4 | 0 |
| DORZOLAMIDE | CA2 | Small molecule | INHIBITOR | Carbonic anhydrase II inhibitor | 4 | 0 |
| ROCURONIUM BROMIDE | CHRNA1 | Small molecule | ANTAGONIST | Muscle-type nicotinic acetylcholine receptor antagonist | 4 | 0 |
| ACETAZOLAMIDE | CA4 | Small molecule | INHIBITOR | Carbonic anhydrase XII inhibitor | 4 | 0 |
| METHAZOLAMIDE | CA2 | Small molecule | INHIBITOR | Carbonic anhydrase II inhibitor | 4 | 0 |
| MIVACURIUM CHLORIDE | CHRNA1 | Small molecule | ANTAGONIST | Muscle-type nicotinic acetylcholine receptor antagonist | 4 | 0 |
| TOPIRAMATE | CA4 | Small molecule | POSITIVE MODULATOR | GABA-A receptor; anion channel positive modulator | 4 | 0 |
| VANTICTUMAB | FZD5 | Antibody | ANTAGONIST | Frizzled-1 antagonist | 1 | 0 |
| ACETAZOLAMIDE SODIUM | CA4 | Small molecule | INHIBITOR | Carbonic anhydrase XII inhibitor | 4 | 0 |
| POLMACOXIB | PTGS2 | Small molecule | INHIBITOR | Carbonic anhydrase I inhibitor | 3 | 0 |
| ROCURONIUM | CHRNA1 | Small molecule | ANTAGONIST | Muscle-type nicotinic acetylcholine receptor antagonist | 4 | 0 |
Causal Flows
Causal Flows are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow a mutation may causally activates or deactivates a downstream regulator which then might up- or down-regulates a regulon that contains genes with similar expression profiles and binding sites.